Analysis of treatment satisfaction and adherence among patients with type 2 diabetes

Background: Low treatment adherence in patients with type 2 diabetes mellitus (T2DM) hinders the effective use of anti-diabetic agents and the achievement of glycemic control, reducing their quality of life and outcomes. Assessment of treatment adherence can help to identify and manage factors and b...

Full description

Bibliographic Details
Main Authors: M. F. Kalashnikova, I. B. Bondareva, N. V. Likhodey, Yu. P. Sych
Format: Article
Language:Russian
Published: MONIKI 2020-12-01
Series:Alʹmanah Kliničeskoj Mediciny
Subjects:
Online Access:https://www.almclinmed.ru/jour/article/view/1405
id doaj-c5e57626734141fb94aae755aaf5679f
record_format Article
spelling doaj-c5e57626734141fb94aae755aaf5679f2021-07-28T21:11:25ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942020-12-0148747648610.18786/2072-0505-2020-48-048769Analysis of treatment satisfaction and adherence among patients with type 2 diabetesM. F. Kalashnikova0I. B. Bondareva1N. V. Likhodey2Yu. P. Sych3I.M. Sechenov First Moscow State Medical UniversityPeoples' Friendship University of Russia (RUDN University)I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityBackground: Low treatment adherence in patients with type 2 diabetes mellitus (T2DM) hinders the effective use of anti-diabetic agents and the achievement of glycemic control, reducing their quality of life and outcomes. Assessment of treatment adherence can help to identify and manage factors and barriers that affect therapy and treatment satisfaction.Aim: To assess the treatment adherence of patients with T2DM, to identify the main barriers to adherence, and patient satisfaction with the treatment.Materials and methods: FORSIGHT-T2DM was a  Russian multiregional, multicenter observational epidemiological study in 2014 patients with T2DM. The patients were assessed with the FORSIGHT- T2DM Patient Questionnaire, Moriski Medication Adherence Scale (MMAS), and Diabetes Treatment Satisfaction Questionnaire (DTSQ).Results: The mean (± SD) treatment adherence estimated using the MMAS was 5.86±1.39 points. The main barriers to adherence were high treatment costs, medication side effects, forgetfulness when taking drugs, complexity of the therapy or treatment regimen. The average number of daily medications was four. There was also a lack of contact with a doctor, poor awareness of the disease and its complications. Ninety (90) per cent of the respondents trusted the recommendations from their doctors, 7.6% followed the advice of relatives or friends. The patient's choice of medication was influenced by information about its effectiveness, its cost, and reimbursement, ease of administration, and information on the absence of side effects. Seventy eight (78) per cent of the respondents were “completely” or “rather” satisfied with their treatment. About 15% of patients rated the quality of care as unsatisfactory.Conclusion: The results of the study identified an intermediate level of treatment adherence in most patients with T2DM, as well as multiple adherence barriers, including comorbidities and the need for continuous intake of various agents. Most patients showed high treatment satisfaction, which could be due to the high availability of outpatient consultations by an endocrinologist and inpatient treatment, free access to anti-diabetic medications. However, it may also be a  result of biased assessment of problems due to insufficient patient awareness of the therapy goals and a low level of knowledge about their disease. To study the factors affecting the adherence to medical recommendations among patients with T2DM, it is necessary to develop a  specific questionnaire for this patient category, which would allow for an evaluation both drug intake and other aspects of their comprehensive treatment, including the identification and analysis of the main barriers to adherence.https://www.almclinmed.ru/jour/article/view/1405adherence to treatmentbarrierstreatment satisfactiontype 2 diabetes mellitus
collection DOAJ
language Russian
format Article
sources DOAJ
author M. F. Kalashnikova
I. B. Bondareva
N. V. Likhodey
Yu. P. Sych
spellingShingle M. F. Kalashnikova
I. B. Bondareva
N. V. Likhodey
Yu. P. Sych
Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
Alʹmanah Kliničeskoj Mediciny
adherence to treatment
barriers
treatment satisfaction
type 2 diabetes mellitus
author_facet M. F. Kalashnikova
I. B. Bondareva
N. V. Likhodey
Yu. P. Sych
author_sort M. F. Kalashnikova
title Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
title_short Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
title_full Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
title_fullStr Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
title_full_unstemmed Analysis of treatment satisfaction and adherence among patients with type 2 diabetes
title_sort analysis of treatment satisfaction and adherence among patients with type 2 diabetes
publisher MONIKI
series Alʹmanah Kliničeskoj Mediciny
issn 2072-0505
2587-9294
publishDate 2020-12-01
description Background: Low treatment adherence in patients with type 2 diabetes mellitus (T2DM) hinders the effective use of anti-diabetic agents and the achievement of glycemic control, reducing their quality of life and outcomes. Assessment of treatment adherence can help to identify and manage factors and barriers that affect therapy and treatment satisfaction.Aim: To assess the treatment adherence of patients with T2DM, to identify the main barriers to adherence, and patient satisfaction with the treatment.Materials and methods: FORSIGHT-T2DM was a  Russian multiregional, multicenter observational epidemiological study in 2014 patients with T2DM. The patients were assessed with the FORSIGHT- T2DM Patient Questionnaire, Moriski Medication Adherence Scale (MMAS), and Diabetes Treatment Satisfaction Questionnaire (DTSQ).Results: The mean (± SD) treatment adherence estimated using the MMAS was 5.86±1.39 points. The main barriers to adherence were high treatment costs, medication side effects, forgetfulness when taking drugs, complexity of the therapy or treatment regimen. The average number of daily medications was four. There was also a lack of contact with a doctor, poor awareness of the disease and its complications. Ninety (90) per cent of the respondents trusted the recommendations from their doctors, 7.6% followed the advice of relatives or friends. The patient's choice of medication was influenced by information about its effectiveness, its cost, and reimbursement, ease of administration, and information on the absence of side effects. Seventy eight (78) per cent of the respondents were “completely” or “rather” satisfied with their treatment. About 15% of patients rated the quality of care as unsatisfactory.Conclusion: The results of the study identified an intermediate level of treatment adherence in most patients with T2DM, as well as multiple adherence barriers, including comorbidities and the need for continuous intake of various agents. Most patients showed high treatment satisfaction, which could be due to the high availability of outpatient consultations by an endocrinologist and inpatient treatment, free access to anti-diabetic medications. However, it may also be a  result of biased assessment of problems due to insufficient patient awareness of the therapy goals and a low level of knowledge about their disease. To study the factors affecting the adherence to medical recommendations among patients with T2DM, it is necessary to develop a  specific questionnaire for this patient category, which would allow for an evaluation both drug intake and other aspects of their comprehensive treatment, including the identification and analysis of the main barriers to adherence.
topic adherence to treatment
barriers
treatment satisfaction
type 2 diabetes mellitus
url https://www.almclinmed.ru/jour/article/view/1405
work_keys_str_mv AT mfkalashnikova analysisoftreatmentsatisfactionandadherenceamongpatientswithtype2diabetes
AT ibbondareva analysisoftreatmentsatisfactionandadherenceamongpatientswithtype2diabetes
AT nvlikhodey analysisoftreatmentsatisfactionandadherenceamongpatientswithtype2diabetes
AT yupsych analysisoftreatmentsatisfactionandadherenceamongpatientswithtype2diabetes
_version_ 1721262283449958400